AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05908526 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Baseline surveys, Cognitive testing and EMAs
Description: Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.
Study NCT05908526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline surveys, Cognitive testing and EMAs
Description: Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.
Study NCT05908526 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Actiwatch
Description: Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.
Study NCT05908526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actiwatch
Description: Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.
Study NCT05908526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant (or placebo)
Description: FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Study NCT05908526 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive substance that looks like the drug or treatment being tested.
Study NCT05028517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMF Connect
Description: The FMF Connect intervention includes cloud infrastructure and an innovative, multilayered mobile app. It incorporates tailored content for parents/caregivers of children (ages 3-12) with FASD or PAE. The app integrates five main components: 1) Dashboard; 2) Learning Modules; 3) Family Forum; 4) Library; and 5) Notebook. Weekly emails are also sent to support motivational engagement.
Study NCT05028517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching
Description: A text-based coaching module is added to the FMF Connect app. Coaches support continued use of the app and individualized goal setting.
Study NCT06218381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very Brief Exposure to Combat Images
Description: In VBE, a series of pictures representing a person's fears (e.g., a combat scene with arousing visuals) is presented very briefly (17 ms), followed by a masking stimulus that prevents conscious recognition of each picture. This sequence of picture-mask stimuli is repeated many times in an exposure session.
Study NCT05786482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online mind-body wellness program
Description: Online program (mindful movement, meditation, breathwork, psychology-based coping skills program)
Study NCT05786482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online mind-body wellness program + Weekly Check-ins
Description: Online program (mindful movement, meditation, breathwork, psychology-based coping skills program) + brief weekly check-ins
Study NCT05409859 — intervention group
Intervention type: OTHER
Intervention: Manual therapies
Description: Manual therapies were determined based on the clinician evaluation and could include spinal mobilization delivered by hands or mechanically assisted and soft tissue therapies.
Study NCT04657081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine (ASTX727)
Description: Route of administration: oral in the form of a tablet
Study NCT04657081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Route of administration: oral in the form of a tablet
Study NCT05057091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 1 - Maitland's Posterior-Anterior Central Vertebral Manipulation
Description: For the posterior-anterior unilateral vertebral manipulation, the therapist positioned both thumbs on top of each other on the spinous process of the vertebra and applied an average of 4 kg of discrete pressure
Study NCT05057091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2- Side-Lying Lumbar Spinal Manipulation
Description: The therapist stood in front of the patient, who was instructed to lie on their side with the painful side facing upward.the therapist utilized their arm and body to apply the manipulation. A high-speed, low-amplitude thrust force was applied in opposite directions: anteriorly to the pelvis and posteriorly to the shoulder.
Study NCT06116552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More Social Stories
Description: Children listen to four stories while looking at accompanying images that contain more social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
Study NCT06116552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Less Social Stories
Description: Children listen to four stories while looking at accompanying images that contain less social information (e.g., characters referencing, dialogue, mental and emotional state words, and narrativity) as measured by a text analysis.
Study NCT06120556 — intervention group
Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: Patients initiating a GLP-1 receptor agonist (i.e. liraglutide, dulaglutide, semaglutide) will be included in the study.
Study NCT05976763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT05976763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation
Study NCT05976763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Observation
Description: Undergo observation
Study NCT05976763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: undergo bone marrow biopsy
Study NCT05032157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 (blinded)
Description: LOU064 (blinded) active treatment
Study NCT05032157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05032157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064 (open-label)
Description: LOU064 (open-label) active treatment
Study NCT05032157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LOU064 (open-label)
Description: LOU064 (open-label) active treatment
Study NCT05519501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyntrFuge System
Description: Microsized Adipose Tissue
Study NCT05519501 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care
Description: Offloading
Study NCT05283720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Subcutaneous Injection (SC)
Study NCT04943445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles
Description: Patients without disease progression will proceed to the concurrent radioimmunotherapy phase of the trial.
Study NCT04943445 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.
Description: Patients without disease progression will proceed to the consolidation immunotherapy phase of the trial.
Study NCT05283720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral; Capsule
Study NCT05283720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral; Capsule
Study NCT05283720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV); Injection
Study NCT05283720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV; Injection
Study NCT05283720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride [HCl]
Description: IV; Injection
Study NCT05283720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral; Tablet
Study NCT05283720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: IV; Injection
Study NCT05976763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: undergo bone marrow biopsy
Study NCT05976763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT05976763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT05976763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT05976763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT05976763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05314855 — intervention group
Intervention type: DEVICE
Intervention: functional MRI
Description: Subjects will undergo functional MRI at 4 time points in 24 hours.
Study NCT06518135 — intervention group
Intervention type: OTHER
Intervention: SLNB group
Description: After the completion of neoadjuvant therapy, axillary SLNB should be performed first before breast surgery; If the frozen pathology SLNs are negative, ALND will no longer be performed; If frozen pathological SLNs are positive, ALND should be performed directly; If frozen pathology is false negative.
Study NCT05283720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral; Tablet
Study NCT05283720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: Oral; Capsule
Study NCT05283720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral; Tablet
Study NCT05175547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clevidipine
Description: Blood pressure management with Clevidipine
Study NCT06217458 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Mammography
Description: The CEM performance protocol involves the intravenous administration of non-ionic, low-osmolarity iodinated contrast medium using an automatic syringe that delivers the required bolus of contrast medium at a dose of 1.5 ml/kg body weight at a rate of 3 ml/s without compressing the breast. After a two-minute pause, necessary to allow the breast parenchyma to absorb (stain) the contrast agent, the patient is positioned for the mammogram and the breast is compressed. First the symptomatic and then the non-symptomatic breast is imaged in two or a total of four standard projections: craniocaudal (CC) and oblique mediolateral (MLO) projections of the breast. The delayed CC and MLO projections of the symptomatic breast are taken within eight minutes of the start of the examination. The delayed mammograms are used to assess the dynamics of the contrast uptake of the lesion and are compared to the same parameters of the breast MRI. The time required to perform the CEM is 8-10 minutes.
Study NCT06220591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superior trunk block
Description: The patient will receive selective supraclavicular nerve block, then will undergo blockage of superior trunk the fifth and sixth cervical nerves of the brachial plexus. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. Then ultrasound probe will be moved to scan the superior trunk the fifth and sixth cervical nerves in the scalene groove.15 cc of local anesthetics mixture will be injected in 0.5 cc aliquots to encircle the fifth \& sixth cervical nerve roots.
Study NCT06220591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clavipectoral fascial plane block
Description: The patient will receive selective supraclavicular nerve block, then will undergo clavipectoral fascial plane block. The operator will scan the supraclavicular nerve on the lateral border of the sternomastoid muscle. Local anesthetics mixture3 cc will be injected in 0.5 cc aliquots after negative aspiration to encircle the supraclavicular nerve. The ultrasound probe will scan both the medial \& lateral ends of the clavicle. Then Local anesthetics mixture15 cc will be injected in 0.5 cc aliquots after negative aspiration between the periosteum of the clavicle and the clavipectoral fascia. The same technique will be conducted on both the lateral and medial ends of the affected clavicle.
Study NCT05757141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosigotifator
Description: Oral Use
Study NCT05456191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Asciminib 80 mg QD administered under fasting conditions.
Study NCT05456191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Description: Nilotinib 300 mg BID administered under fasting conditions.
Study NCT04753658 — intervention group
Intervention type: DRUG
Intervention: lorlatinib
Description: Oral
Study NCT05264376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Body Project
Description: The Diabetes Body Project (DBP) is an adapted version of the Body Project Prevention program designed specifically for individuals with Type 1 Diabetes. DBP consists of six weekly, one-hour long sessions. Group participants complete the exercises from the original Body Project and also new diabetes-specific content, drawn from Olmsted et al. (2002) that is delivered in a dissonance-based interactive format with Socratic questions from group leaders encourage participants to generate their own answers.
Study NCT05264376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control
Description: We selected a T1D management/Eating disorder psychoeducational comparison condition previously tested (Olmsted et al., 2002) to control for expectancy effects and demand characteristics. To match the Diabetes Body Project, the educational lectures by Dr. Olmsted will be delivered in 6 1-hour blocks. Topics include basic information about the various EDs, complications of ED behaviors, diabetes and body image, effects of dieting on blood glucose, and the risk of complications.
Study NCT05515588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517 (C-14)
Description: BI 690517 (C-14)
Study NCT05515588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Description: BI 690517
Study NCT06186336 — intervention group
Intervention type: OTHER
Intervention: Deep Learning-based Vulnerable Plaque Detection and Assessment Tool
Description: Scanning requirements for the clinically indicated CCTA and ICA with OCT will be performed according to current site(s) guidelines and procedures. Administration of medications (such as contrast agents and potentially beta-blockers and other medications) will be given according to standard hospital care.~This is a prospective research study evaluating an investigational product. The tool's use is intended for research purposes and is not intended as a substitute for required medical care. The CCTA and ICA with OCT will be processed in real-time using the site's locally available post-processing tools in order to guide the subject's medical care. Once the ICA with OCT is complete, the de-identified CCTA data will be inputted in the investigational tool.~The clinically indicated CCTA and the ICA with OCT will both take approximately 1 hour and will take place within 10 days. No additional imaging is needed as part of the study.
Study NCT04943445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.
Description: Consolidation immunotherapy
Study NCT06216548 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care and Enhanced Primary Care
Description: Usual Care: Interdisciplinary complex care teams help coordinate appointments, facilitate communication between the many specialist providers involved in the child's care, support families, assist with practical needs, and are available as a resource (as consultants) for Primary Care Physicians (PCPs) to care for Children with Medical Complexity (CMC). The complex care teams in tertiary care children's hospital is the focus for providing comprehensive care for CMC.~Enhanced Primary Care: The E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. A team of telehealth experts will help PCPs in using telehealth in their practice.
Study NCT06216548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Primary Care
Description: The intervention has the following components: (A) The staff of the E-PRIME team will support the CMC and their caregivers with navigating the patient access portal and how to use the video visit platform for the telehealth visits. (B) The physician or nurse of the E-PRIME team will create clinical summaries about CMC's visit to specialists and hospital and share this health information about CMC with his/her PCP to help the PCP provide care for CMC at home. (C) A team of telehealth experts will help PCPs in using telehealth in their practice.
Study NCT06116968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aficamten
Description: 5-20mg
Study NCT05184062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 600 mg AZD7442 IV
Description: Participants will be randomized to receive co-administration of 600 mg AZD7442 (300 mg AZD8895 and 300 mg AZD1061) by a single IV infusion.
Study NCT05184062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 600mg placebo IV
Description: Participants will be randomized to receive co-administration of 600mg placebo by a single IV infusion.
Study NCT06694441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light Exposure
Description: The intervention in this study will involve 28 (+4) days of daily exposure to bright light (BL) for two 60-minute sessions (morning and afternoon). For the intervention, we will use Re-Timer® light glasses emitting light with an intensity of 230μW/cm2 (\~500lux) with a green blue 500nm dominant wavelength (between 480-520nm). Light with these characteristics has been shown effective in suppressing melatonin levels supporting their potential to exert effects on other biological non-visual functions associated with exposure to light relevant for this study. Throughout the intervention, participants will keep a diary to monitor daily use of the glasses. Participants will have weekly phone calls with the research team to encourage compliance and monitor potential side effects.
Study NCT06694441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the control group will wear for two 60-minute sessions (morning and afternoon) customized dim-red light (RL) control Re-Timer® light glasses (wavelength peak at 632nm, light intensity \< 3 lux).
Study NCT06687148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual manipulation
Description: The participants will receive one session of manipulation if in the experimental group. It should be mentioned that the technique will be carried out by a physiotherapist with a history of more than 10 years of manual therapy. For instance, to correct right anterior innominate rotation, the participant will be made to lie on the side so that the affected side is upward. The physiotherapist will stand in front of the participant; first we will put their shoulders, pelvis and lower limbs in neutral position and place the right hand on the anterior superior iliac spine (ASIS) and the left hand on the ischium tuberosity and with a rotational movement of the hands, the physiotherapist will rotate the ilium posteriorly. At the end of the range, we will replace the position of hands and place the left forearm on the ischium tuberosity and place the right hand on the upper participant's shoulder and will move it toward the bed at the end of the range in exhalation a thrust will be executed.
Study NCT06155656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein concentrate
Description: Ingestion of a soup containing 25 g of protein from pea protein concentrate
Study NCT06155656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein isolate
Description: Ingestion of a soup containing 25 g of protein from pea protein isolate
Study NCT06155656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea protein extrudate
Description: Ingestion of a soup containing 25 g of protein from pea protein extrudate
Study NCT06155656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: Ingestion of a soup containing 25 g of protein from whey protein
Study NCT05148442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI322
Description: Recombinant anti-human CD47/PD-L1 bispecific antibody
Study NCT04137653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel+carboplatin
Description: Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.